// App-Quantinova.ai

: Cost-Effectiveness of Defibrotide for the Treatment of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) with Multi-Organ Dysfunction (MOD) Post-Hematopoietic Stem Cell Transplantation (HSCT) in Canada

Researchers

Presenter

  • Jonathan Belsey

Principal Investigators

  • Eric Ngonga Kemadjou

  • Maya Isaila

  • Kathleen F. Villa

Medical Centers

  • JB Medical Ltd, Sudbury, Suffolk, United Kingdom

  • Jazz Pharmaceuticals, Oakville, Canada

  • Jazz Pharmaceuticals, Palo Alto, CA

Locations

  • United Kingdom

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Hepatic veno-occlusive disease with immunodeficiency

  • End-stage liver disease

  • Fulminant hepatic failure

Biomarkers

  • Solute Carrier Family 12 Member 2

Drug/Treatment

  • Defibrotide

Outcome

  • N/A

Study Design

  • N/A

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved